deamidation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Reviewing the film's 2020 premiere, The Hollywood Reporter's John DeFore noted not only the quality of Henriksen's performance, but the opportunity Mortensen's script presented: "[F]ew moviegoers who've enjoyed him over the years will be surprised, but many will resent that we, and he, have waited so long for a role like this." He received a Canadian Screen Award nomination for Best Actor at the 9th Canadian Screen Awards in 2021, for his performance in Falling. In 2022, Henriksen was cast in the upcoming American horror film, Awaken the Reaper. The film is currently shooting in New York and slated for a 2024 release date. It is directed by Justin Paul and Dave Campfield and produced by Fourth Horizon Cinema, Impact Media Studios and Design Weapons.
=== Beginnings === In September 1935, British chocolate manufacturer Rowntree's brought the first aerated chocolate, Aero, to market. At the time, Rowntree's had been struggling for several years to compete with rival chocolate maker Cadbury's Cadbury Dairy Milk and was looking for a new product to gain an advantage. The new chocolate was the outcome of significant research focused on developing a "count line" chocolate inspired by the recent introduction of the Mars bar to the UK market. Rowntree's patented their aerated chocolate broadly, covering variants such as chocolate with inclusions. As it was released to market, the new chocolate garnered strong sales and positive reviews, although some concerns were voiced within Rowntree's that the product would be a novelty. In their initial marketing, Rowntree's promoted aerated chocolate as better than solid chocolate: more digestible and lacking its "cloying after-taste". Cadbury objected to this and petitioned Rowntree's to stop denigrating rival chocolate makers in marketing.Rival chocolate markers attempted to position their existing product lines as competition (Cadbury their crumbly Flake bars, and Fry's their aerated-honeycomb-filled Crunchie bars), but none were seen by customers as "aerated" in the same sense as Aero. Further to their objections about aerated chocolate's digestibility, Cadbury contested the validity of the patent itself, arguing it overstepped and covered chocolates Cadbury already manufactured, as well as being malformed.
After his election in 1994, Nelson Mandela encouraged black South Africans to get behind the previously hated national rugby team, the Springboks, as South Africa hosted the 1995 Rugby World Cup. Prior to the World Cup in 1995, the Springboks were only seeded ninth and were not expected to dethrone the incumbent champions Australia, who had not lost a game in the preceding 12 months. During the tournament, South Africa defeated Australia, Romania, Canada, Western Samoa and France. They then met New Zealand in the 1995 Rugby World Cup Final at Ellis Park Stadium. Springbok captain Francois Pienaar played on in extra-time despite a calf strain and the Springboks secured a three-point victory with a drop goal from Joel Stransky. During the remarkable post-match presentation ceremony, Nelson Mandela presented Pienaar with the Webb Ellis Cup while wearing a Springbok jersey bearing Pienaar's own number 6. During his acceptance speech, Pienaar made it clear that the team had won the trophy not just for the 60,000 fans at Ellis Park, but also for all 43,000,000 South Africans. This was widely seen as a major step in the reconciliation of white and black South Africans; as F.W. de Klerk later put it, "Mandela won the hearts of millions of white rugby fans." Mandela's efforts at reconciliation assuaged the fears of whites, but also drew criticism from more militant blacks. His estranged wife, Winnie, accused the ANC of being more interested in appeasing whites than in helping blacks.
shotgun sequencing A method of sequencing entire genomes in which genomic DNA is randomly fragmented (e.g. by sonication or restriction digests), cloned into plasmid vectors, and then sequenced using primers that anneal to flanking sequences in the plasmids. Computer software is used to align the sequenced fragments via overlapping contigs, allowing scientists to deduce the relative genomic locations of each fragment and thereby assemble a complete genome.
=== Fatty acid uptake === Long chain fatty acid uptake is mediated by several transporters, including FAT (fatty acid translocase)/CD36. CD36 deletion rescues lipotoxic cardiomyopathy. FAT/CD36 may be controlled by insulin and AMPK. Increased transport coupled to the formation of the CoA derivatives and the resulting AMPK activation should ensure efficient fatty acid uptake and metabolism.
Sources: en.wikipedia.org
By the end of the 18th century, Cossack nations had been transformed into a special military estate (sosloviye), "a military class". The Malorussian Cossacks (the former Registered Cossacks also known as "Town Zaporozhian Host") were excluded from this transformation, but were promoted to membership of various civil estates or classes (often Russian nobility), including the newly created civil estate of Cossacks. Under a semi-feudal system retained until the end of the Russian Empire, Cossack families received grants of land which they retained free of taxation, provided that commitments to perform military service were met. Typically a single father or son from each registered family would serve several years full-time with his Host before becoming a reservist liable for recall only in the event of emergency or general mobilisation. When joining his regiment a Cossack was required to bring his own horse, uniform clothing, and basic weaponry (sabres and lances) although the larger and more affluent Hosts might assist in sourcing these essentials. The Russian central government provided only firearms plus food and accommodation. Lacking horses, the poor served in the Cossack infantry and artillery. In the navy alone, Cossacks served with other peoples as the Russian navy had no Cossack ships and units. Cossack service was considered rigorous.
=== Xenobiotics === Numerous drugs can raise GGT levels, including phenobarbitone and phenytoin. GGT elevation has also been occasionally reported following nonsteroidal anti-inflammatory drugs (including aspirin), St. John's wort and kava.
== Prescription labels == Medication packaging includes a document that provides information about that drug and its use. In the US, this information is overseen by the Center for Drug Research and Evaluation (CDER), a branch of the Food and Drug Administration (FDA). For prescription medications, the insert is technical, and provides information for medical professionals about how to prescribe the drug. Package inserts for prescription drugs often include a separate document called a "patient package insert" with information written in plain language intended for the end-user -- the person who will take the drug or administer the drug to another person. Inserts for over-the-counter medications are also written plainly. In the US the document is called "prescribing information" or the "package insert" (PI) and layperson's document is called the "patient package insert" (PPI). In Europe the technical document is called the "summary of product characteristics" and the document for end-users is called the "package leaflet". The bottle or box also has information printed on it, intended for the person taking the medication.
Modern isolation and membrane technologies, like reverse osmosis, ultra- and nano-filtration and affinity chromatography can help to remove salts and by-products, and concentrate the solution efficiently and in an environmentally friendly manner under mild conditions. The final purification is often achieved by conventional chemical crystallization processes. In contrast to the isolation of small molecules, the isolation and purification of microbial proteins is tedious and often involves a number of expensive large-scale chromatographic operations. Examples of large-volume LMW products made by modern industrial microbial biosynthetic processes are monosodium glutamate (MSG), vitamin B2 (riboflavin), and vitamin C (ascorbic acid). In vitamin B2, riboflavin, the original six- to eight-step synthetic process starting from barbituric acid has been substituted completely by a microbial one-step process, allowing a 95% waste reduction and an approximately 50% manufacturing cost reduction. In ascorbic acid, the five-step process (yield ≈ 85%) starting from D-glucose, originally invented by Tadeus Reichstein in 1933, is being gradually substituted by a more straightforward fermentative process with 2-ketogluconic acid as pivotal intermediate. After the discovery of penicillin in 1928 by Sir Alexander Fleming from colonies of the bacterium Staphylococcus aureus, it took more than a decade before a powdery form of the medicine was developed.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Ice formation concentrates solutes and can mechanically stress the peptide or damage the delivery device. Thawing afterwards may leave aggregates that are not visible to the eye. Refrigeration keeps the solution above its freezing point while slowing chemical degradation.